Table 1.
Clinical characteristics of patients
| Characteristics | Values |
|---|---|
| Age [median (range)] | 16.5 (12–24) years |
| Sex [n (%)] | |
| Male | 18 (75%) |
| Female | 6 (25%) |
| Location of primary tumour [n (%)] | |
| Femur | 17 (64%) |
| Tibia | 15 (43%) |
| Shoulder | 3 (1%) |
| Tumour-volume [median (range)] | 412.84 (87.01–3559.46) cc |
| Metastasis at diagnosis [n (%)] | |
| Metastatic | 11 (31%) |
| Localized | 24 (69%) |
| Alkaline phosphatase [median (range)] | 412 (134–7980) IU/L |
| Lactate dehydrogenase [median (range)] | 303 (173–665) U/L |
| Histopathological response evaluation | |
| Percentage of necrosis [median (range)] | 30 (0–99) % |
| Good response [n (%)] | 13 (37%) |
| Poor response [n (%)] | 22 (63%) |
| Survival outcome evaluation | |
| Follow-up time [median(range)] | 25.93 (7.6–54.4) months |
| Event free survival [n (%), median (range) time] | 11 (31%), 16.27 (5.5–54.4) months |
| Overall survival [n (%), median (range) time] | 24 (69%), 25.9 (7.6–54.4) months |